Introduction to Product Decisions
This unit is centered on ‘The Product’, the most fundamental element of the marketing mix. It covers how a pharmaceutical company builds a portfolio (Product Mix vs. Product Line), how it strategically guides a specific drug through the stages of its Product Life Cycle (PLC), and the frameworks used to analyze profitability (like the BCG matrix). Additionally, it explores the critical decisions regarding drug branding, packaging (for compliance and safety), and regulatory labeling.
Syllabus & Topics
- 1Product Basics & Classification: A product is anything offered to a market for attention, acquisition, or consumption. In pharma, products are broadly classified into OTC (Over-the-Counter/non-prescription) and Ethical (prescription-only) drugs, or based on therapeutic categories (Antibiotics, NSAIDs).
- 2Product Line and Product Mix Decisions: Product Mix (Portfolio): The total sum of all product lines a company offers (e.g., GSK’s mix includes vaccines, respiratory inhalers, and consumer healthcare). Mix Width: Number of different product lines. Product Line: A group of closely related products (e.g., a line of cardiovascular drugs). Line Depth: Number of variants within a line (e.g., Amlodipine 5mg, 10mg, and Amlodipine+Lisinopril combo). Companies constantly decide whether to stretch/lengthen a line or prune unprofitable items.
- 3The Product Life Cycle (PLC): Every product goes through 4 distinct phases, requiring different marketing strategies: (1) Introduction: Drug is newly launched against patent. High R&D/promotional costs, low sales, negative profits. Strategy: Create extreme disease awareness among specialists. (2) Growth: Rapid market acceptance, profits surge, competitors enter. Strategy: Maximize market share, expand to general physicians. (3) Maturity: Sales peak but plateau as market saturates with ‘me-too’ competitor drugs. Profits are high but slowly dropping. Strategy: Defend market share, competitive pricing, launch line extensions. (4) Decline: Sales plummet due to patent expiry, generic erosion, or better newly-invented molecules. Strategy: Milk the brand, cut promotional costs entirely, or legally discontinue.
- 4Product Portfolio Analysis: Crucial for a multi-product company to decide where to invest cash. Usually analyzed via frameworks like the BCG (Boston Consulting Group) Matrix, which plots products based on Market Growth Rate vs. Relative Market Share: (1) Stars (high growth, high share): Require heavy investment. (2) Cash Cows (low growth, high share): Mature products generating massive cash to fund Stars. (3) Question Marks (high growth, low share): Need strategy to convert to Stars, or else drop them. (4) Dogs (low growth, low share): Liquidate or divest.
- 5Product Positioning: The deliberate act of designing the company’s offering to occupy a distinct, valued place in the target doctor’s mind compared to competitors. Positioning can be based on specific attributes (e.g., ‘The fastest-acting antacid’), specific usage (e.g., ‘The only once-weekly osteoporosis pill’), or safety (e.g., ‘Safest NSAID for cardiac patients’).
- 6New Product Decisions & Branding: New Product Development (NPD) involves idea generation, clinical screening, business analysis, and commercialization. Product Branding: Creating a unique name, sign, or symbol. A strong brand (Brand Equity) allows a company to charge premium prices and creates intense loyalty (e.g., ‘Crocin’ vs. generic paracetamol). Brand names must be memorable, easy to pronounce globally, and legally protectable (trademarked).
- 7Packaging and Labeling Decisions: Packaging is the ‘silent salesman’ and is heavily regulated. Functions: Protection (light/moisture resistance), Convenience (easy-to-use inhalers/droppers), Compliance (calendar blister packs detailing Days of the Week for birth control), and Promotion. Labeling: Strictly governed by the Drugs and Cosmetics Act. Must include generic name, brand name, schedule warnings (e.g., ‘Schedule H Warning: To be sold by retail on prescription only’), batch number, expiry date, manufacturing license number, and specific storage instructions.
Learning Objectives
Exam Prep Questions
Q1. What exactly happens to a drug during the “Decline” phase of the Product Life Cycle?
In pharma, the most sudden cause of the “Decline” phase is the “Patent Cliff” (the expiration of a 20-year formulation patent). Overnight, multiple competitor companies legally launch exact generic copies of the drug at 80% cheaper prices. Sales and profits of the original branded innovator drug plummet. The marketing strategy usually shifts to drastically slashing advertising budgets and just relying on residual brand loyalty from older patients (milking the product).
Q2. Why is a “Cash Cow” so important to a pharmaceutical company?
In the BCG Matrix, a Cash Cow is a product that holds a massive market share in a mature, slow-growing industry (think of a common, widely prescribed painkiller brand). Because it is mature, the company doesn’t need to spend much on advertising or R&D for it anymore. Therefore, it generates massive profit (cash). The company literally “milks” this cash cow to fund the phenomenally expensive R&D required to invent new molecules (“Question Marks” and “Stars”).
Q3. How can packaging act as an active marketing tool in pharmacy?
In consumer goods, packaging attracts the eye. In pharmacy, modern packaging drives “Patient Compliance”, which indirectly drives sales. For example, oral contraceptives packaged in a “dial-pack” mimicking the calendar days of the month ensure the patient doesn’t miss a pill. A steroid inhaler packaged with a built-in dose counter reassures the patient. These functional packaging innovations become key selling propositions that representatives highlight to doctors to gain prescriptions.